-
Understanding Stress and Alcohol Use in College-Aged Women
Official Title Examining the Role of Sensitivity to Uncertain Threat and Alcohol Response in Risk for AUD following Sexual Assault in College WomenPurpose
The purpose of this study is to better understand how stress relates to alcohol use in biological females aged 21-29.
Participation in the study includes three in-person visits and the completion of daily phone surveys across 21 days while wearing a biosensor, which is similar to a Fitbit or smart watch. The first lab visit includes screening and orientation with blood draw, EKG, and sensory tasks. The second and third lab visits include sensory tasks and intravenous alcohol or placebo (a saline solution) administration. Participation in the study occurs over a period of 7 weeks.
Could this study be right for you?
Inclusion Criteria:
-
Biological female
-
21-29 years old
-
At least a high school education
-
Fluency in English
-
Drink alcohol regularly
(partial list of inclusion criteria)
Exclusion Criteria:
-
Current pregnancy
-
Lifetime history of psychosis
(partial list of exclusion criteria)
Age Range
21 - 29 years -
-
Study of Pain Sensitivity and Responses to Alcohol
Official Title Pain Sensitivity, Alcohol-Induced Analgesia, and Heavy Drinking in Individuals with Opioid Use DisorderPurpose
The purpose of this study is to better understand how pain and related emotions change during sobriety and after drinking alcohol.
The length of the study is approximately 4 weeks and will include three on-campus lab visits at Ohio State's Medical Campus. The first lab visit includes screening and orientation with blood draw, EKG, and sensory tasks. The second and third lab visits include sensory tasks and intravenous alcohol or placebo (a saline solution) administration. The total time commitment of the study is approximately 17 hours.
Could this study be right for you?
Inclusion Criteria:
For this study, we are looking for people ages 21–65 who meet one of the following:
- Drink alcohol regularly
- Drink alcohol regularly and use opioids
- Occasionally drink alcohol and use opioids
(partial list of inclusion criteria)
Exclusion Criteria:
- Sensitivity to alcohol
- Current pregnancy
- Current or past diagnosis of mania or psychosis
(partial list of exclusion criteria)
Age Range
21 - 65 years -
EEG Research Study
Official Title Neural Biomarkers of Sensory Symptoms in AutismPurpose
This research aims to understand how sensory issues, particularly related to hearing, impact children on the autism spectrum. Using a tool called EEG, we study how their brains respond to sounds. Previous research with adults on the spectrum showed that their brains react more slowly to sounds, affecting their ability to pay attention. This protocol investigates if a similar pattern exists in children with autism.
Could this study be right for you?
We are searching for healthy neurotypical boys aged 8-12.
Age Range
8 - 12 years -
Comparing Tongue Strength and Endurance Before and After Eating a Meal
Official Title Impact of Meal Consumption on Lingual EndurancePurpose
The purpose of this study is to understand how eating a meal can affect muscle fatigue in the tongue in individuals with swallowing difficulties due to a neurological disorder or history of a stroke.
If you choose to participate, you will:
- Complete questionnaires about your swallowing and overall health.
- Participate in measurements of your tongue strength using a small, soft bulb placed in your mouth.
- Eat a standard meal of chicken, masked potatoes and green beans.
- Remeasure your tongue and grip strength after the meal
This study is completed in 1 session that lasts approximately 90 minutes.
Could this study be right for you?
- 18 years of age or older
- Report at least some signs/symptoms of difficulty swallowing (dysphagia)
- Have a diagnosed neurological disorder
- English speaking
- Able to eat a standardized meal of chicken, green beans and mashed potatoes
- Adequate dexterity to self-administer foods and drink via fork and cup
Age Range
18 - 100 years -
Evaluating the Efficacy of a Psychedelic Investigational Drug for Patients who are Struggling with Symptoms of Depression and Anxiety due to Cancer or Other Life-Changing Medical Illness
Official Title A Randomized, Double-Blind, Parallel-Group, Dose-Controlled Study Evaluating the Safety and Efficacy of RE104 for Injection in the Treatment of Adjustment Disorder in Patients with Cancer and Other Medical IllnessesPurpose
The purpose of this study is to determine if treatment with a single dose of RE104 for Injection reduces depressive symptoms or depressive symptoms mixed with anxiety symptoms in participants with Adjustment Disorder due to cancer or other illnesses such as Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), Parkinson's Disease (PD) or Idiopathic Pulmonary Fibrosis (IPF) as compared to active-placebo.
Could this study be right for you?
- Depression due to cancer, Parkinson’s, ALS, MS, or IPF
- Currently depressed
- Projected life expectancy of ≥6 months.
Age Range
18 - 80 years -
How Do Ketone Supplements Affect Brain Function in Healthy Adults
Official Title Effects of Acute Ketone Supplementation on the Brain (KETO-BRAIN)Purpose
This study looks at how ketone drinks affect the brain in healthy adults. Ketones are natural substances your body makes when it breaks down fat for energy. Scientists think ketones might help protect the brain and improve how it works.
We want to learn if drinking a ketone supplement changes blood flow to the brain and affects brain chemicals that help with thinking and memory. This information could help us understand if ketone drinks might be helpful for brain health as people age.
If you join this study, you will:
- Come to the research center 3 times over about 1-2 weeks
- Drink either a ketone supplement or a comparison drink (you will not know which one)
- Have brain scans using an MRI machine (like a large medical camera)
- Take simple thinking tests on a computer
- Have finger stick blood tests to measure ketone and sugar levels
You will first come in for a consent visit that take about 1 hour. Then, you will return for two more visits that will take about 3 hours each. You will drink a special beverage twice a day for two days before each scan visit. The study uses MRI scans to safely take pictures of your brain without radiation. We will measure blood flow in your brain and certain brain chemicals before and after you drink the supplement.
This research may help scientists better understand how ketones work in the brain. This could lead to new ways to support brain health in the future.
Could this study be right for you?
Who Can Join:
- Body Mass Index (BMI) between 18.5 and 30
- Able to skip eating overnight before study visits
- Not following a keto diet
Who Cannot Join:
- People who do not speak English
- Currently using ketone supplements or following a keto diet
- Pregnant or breastfeeding
- Allergic to milk protein or lactose intolerant
- History of high blood pressure
- History of alcohol problems in the past 2 years
- History of illegal drug use
- Head injury that caused loss of consciousness
- Brain or nerve disease diagnosis
- Taking medications for mental health conditions
- Current smokers
- Anyone with metal in their body or other reasons they cannot have an MRI scan
Age Range
45 - 65 years -
A Study to Evaluate Investigation Drug, BHV-7000, in Patients with Refractory Focal Onset Epilepsy
Official Title A Phase 2/3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy, Safety and Tolerability of BHV-7000 in Subjects with Refractory Focal Onset EpilepsyPurpose
This research is being done to see the effectiveness and safety of a new drug called BHV-7000 as a possible treatment for focal seizures for patients who are taking anti-seizure medications (ASMs) and still experiencing seizures. Refractory focal epilepsy is when someone continues to have focal seizures despite treatment with ASMs or other treatments.
People who take part in this study will be randomly assigned to either study medication or a placebo, will participate for up to 5 months, and the study includes up to 7 in-person visits.
Could this study be right for you?
- Experiencing at least 4 or more observable focal seizures per month
- Taking at least 1 and up to 3 anti-seizure medications
- Do not have a history of cluster/repetitive seizures (which you were not able to individually count) in the past 6 months
- Between the ages of 18 to 75
Age Range
18 - 75 years -
Phase 3 Study to Evaluate Investigational Drug, XEN1101, in Patients with Primary Generalized Tonic-Clonic Seizures: XPF-010-303
Official Title A Randomized, Double-blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic SeizuresPurpose
In this research study a study drug named XEN1101 is being tested for the treatment of seizures. The main purpose of this study is to determine if XEN1101 can reduce the seizure frequency and if it is safe to use. People who take part in this study will be randomly assigned to either study medication or a placebo, will participate for up to 5 months, and includes up to 7 in-person visits.
Could this study be right for you?
- Experiencing at least 3 PGTCS in an 8-week period
- Have tried at least 2 anti-seizure medications without success
- Do not have a history of cluster/repetitive seizures (which you were not able to individually count) in the past 12 months
- 18 years old and up
Age Range
18 years and up -
Effect of Diet and Electrical Stimulation Exercise on Blood Pressure Control in Spinal Cord Injury
Official Title Lifestyle solutions to postprandial hypotension in spinal cord injuryPurpose
To test if a low-glycemic diet and electrical stimulation of leg muscles can improve blood pressure control after eating.
Could this study be right for you?
- Spinal cord injury sustained at least 1-year ago
- Level of injury between C4 and T10
- Use of wheelchair for majority of daily activities
Age Range
18 years and up -
A First-in-human Study of a New Gene Therapy (AMT-260) in Adults with Unilateral Refractory Mesial Temporal Lobe Epilepsy (MTLE)
Official Title A Multi-center, Phase 1/2a, First-in-human (FIH) Study Investigating the Safety, Tolerability, and Efficacy of AMT-260 in Adults with Unilateral Refractory Mesial Temporal Lobe Epilepsy (MTLE) Administered via Magnetic Resonance Imaging (MRI)-guided Convection-enhanced Delivery (CED)Purpose
You are being invited to participate in a study about mesial temporal lobe epilepsy (MTLE) on only 1 side (unilateral) of the brain that has not responded to medication (refractory).
The study will test AMT-260, which is a new gene therapy under investigation for use in treating people like you with MTLE. It is not yet approved as a drug for treating MTLE. It can only be used in a study like this one. This is the first time this gene therapy will be used in humans. It has previously been studied in animals.
AMT-260 is a gene therapy designed to reduce the electrical signals between nerve cells (neurons) in the parts of your brain where nerve cells are abnormally connected. This reduces the extra electrical signals that happen at the same time and is intended to reduce your seizure activity.
The overall goals of this study are:
- To observe whether participants have any side effects from AMT-260 or from the procedure to deliver AMT-260 into the brain and how well participants tolerate any side effects that may occur.
- To measure if participants have changes in:
- frequency of their seizures
- how their seizures affect their life
- how the human body takes up and removes AMT-260
- To find the best dose of AMT-260 for future participants to ensure clinical benefit with minimal or no side effects.
Could this study be right for you?
Adult, 18-65 years of age, inclusive, capable of giving informed consent.
Written informed consent is given freely after the nature of the study has been explained to the participant and the completion of data disclosure.
Willingness to undergo necessary surgical procedures.
Diagnosis of unilateral refractory MTLE for ≥360 days, confirmed by an Epilepsy Monitoring Unit.Additional Eligibility Criteria to be assessed by neurosurgery team, and as described in the study protocol.
Age Range
18 - 65 years